SF-30_Solicitation_amendment.pdf

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

(a) By completing items 8 and 15, and returning or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment your desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

E. IMPORTANT: Contractor is not, is required to sign this document and return copies to the issuing office.

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE

2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable)

7. ADMINISTERED BY (If other than Item 6) CODE

STANDARD FORM 30 (REV. 10-83)

Prescribed by GSA FAR (48 CFR) 53.243

FACILITY CODE

9A. AMENDMENT OF SOLICITATION

NO.

9B. DATED (SEE ITEM 11)

10A. MODIFICATION OF CONTRACT/ORDER NO.

10B. DATED (SEE ITEM 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended.

12. ACCOUNTING AND APPROPRIATION DATA (If required) copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS.

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO.

IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15C. DATE SIGNED

15A. NAME AND TITLE OF SIGNER (Type or print)

16C. DATE SIGNED

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

PAGE OF PAGES

6. ISSUED BY CODE

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (X)

CODE

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

16B. UNITED STATES OF AMERICA

(Signature of Contracting Officer)

NSN 7540-01-152-8070

Previous edition unusable

pg. 2

TITLE: Brand Name or Equal Covaris ME220 Focused Ultrasonicator for chromatin and DNA shearing.

GENERAL INFORMATION

Document Type: Combined Synopsis / Solicitation Notice

Solicitation Number: 75N91019Q00070

Proposed Posted Date: July 5, 2019

Proposed Response Date: July 12, 2019

Classification Code: 66 – Instruments & laboratory equipment

NAICS Code: 334516 – Analytical Laboratory Instrument Manufacturing

Business Size Standard: 1,000 Employees

CONTRACTING OFFICE ADDRESS

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E126, Bethesda, MD 20892, UNITED

STATES.

Non-USPS mail such as FedEx, UPS and other private carriers please use Rockville, MD 20850.

The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Laboratory of Translational Genomics (LTG), plans to procure one (1) Brand Name or Equal Covaris ME220 Focused Ultrasonicator that will be used primarily for chromatin and DNA shearing.

This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation:

No. 75N91019Q00070 includes all applicable provisions and clauses in effect through FAR FAC 2019-03 (June 2019) simplified procedures for commercial items.

This acquisition is a 100% small business set-aside. The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees.

Only one award will be made as a result of this solicitation. This will be awarded as a Severable Firm Fixed Price type contract.

The services acquired under this contract are severable services. Funds are only available for use for the contract line item (CLIN) to which they are obligated. Unused funds from one CLIN may not rollover for use in other periods.

DESCRIPTION OF REQUIREMENT

The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Laboratory of Translational Genomics (LTG), plans to procure one (1) Brand Name or Equal Covaris ME220 Focused Ultrasonicator that will be used primarily for chromatin and DNA shearing. The Laboratory of Translational Genomics (LTG) conducts studies on germline and somatic genetics of cancer, and analyses

pg. 3 on particular regions of the genome conclusively identified in cancer-specific genome-wide association studies (GWAS) and linkage studies in high-risk families.

LTG's mission is to understand the contribution of germline and somatic genetic variation to cancer etiology and outcomes. Its primary goals are to investigate regions of genetic variation by:

• Detecting cancer susceptibility alleles

• Fine mapping susceptibility alleles using sequence analysis and imputation from public databases

• Prioritizing variants for follow-up studies through bioinformatic analysis of candidate variants

• Deciphering the biological mechanisms underlying susceptibility alleles through laboratory investigation

This requirement will also assist the NCI with investigating the genetic basis of strong association signals identified in candidate gene association studies, linkage analyses in high-risk families, or genome-wide association studies (GWAS.)

PRODUCT FEATURES/SALIENT CHARACTERISTICS

This requirement is for a Brand Name or Equal Covaris benchtop focused ultrasonicator. The Contractor shall provide the following product features/salient characteristics required for this requirement:

• Adaptive focused acoustics technology for increased reproducibility and sensitivity

• Integrated chiller and water management o Automatic water level setting o Automatic water chilling o No degas required

• Can process 1-4 samples in one batch o Consumables and all other parts required for processing sample volumes of 130 uL, 500 uL, and 1000 uL

• Instrument can process sample volumes of 15 – 1000 uL

• DNA/chromatin shearing to size range 130bp – 6 kb

• Fast start up time. Less than 5 minutes from powering the unit on to processing samples

• Must not require hearing protection for operators

• Computer and required operating software included

• Instrument must not exceed 20x20x20 inches (excluding computer, monitor, keyboard)

• Power 110V, NEMA 5-15 plug type

• At least 1-year warranty

• Installation and training included

• All shipping costs must be included in the quote. The NCI will not be responsible for shipping costs after an award is made, if costs were not included in the quote

• The instrumentation shall complete all steps for hybridization, washing, and imaging without user intervention and shall be compatible with microarrays for pharmacogenomics, customizable cancer genetic analysis, expanded carrier screening, and genome-wide association studies for targeted populations

• Coordination of delivery, installation and training with the NCI Technical Point of Contact

(TPC)

DELIVERY / INSTALLATION

The Contractor shall deliver the systems within two (2) weeks 45 days after award to:

National Cancer Institute

pg. 4

8717 Grovemont Circle Gaithersburg, Maryland 20877

TRAINING

The Contractor shall provide installation and training within 1 week of delivery. The training shall occur at the delivery location and last 1-1.5 hours to cover the following topics:

-Principles of Adaptive focused acoustics (AFA) and shearing -Daily and monthly maintenance requirements -Selection of appropriate consumables for sample type and application, -Instrument startup -Running standard methods -Programming and running custom methods -Instrument shut down

PAYMENT

Payment shall be made in arrears after delivery and acceptance of the NCI TPC. Payment authorization requires submission and approval of invoice to the NCI TPC and NIH Commercial Accounts.

BASIS OF AWARD

The purchase order will be awarded to the Lowest Price Technically Acceptable (LPTA). The award will be made on the basis of the lowest evaluated price of quotations meeting or exceeding the acceptability standards for the requirements/technical specifications stated above. The technical evaluation will be a determination based on information furnished by the vendor. The Government is not responsible for locating or securing any information which is not identified in the quote. The Government reserves the right to make an award without discussions.

PROVISIONS AND CLAUSES

The following FAR provisions and clauses apply to this acquisition:

FAR 52.211-6 Brand Name or Equal. (Aug 1999)

(a) If an item in this solicitation is identified as “brand name or equal,” the purchase description reflects the characteristics and level of quality that will satisfy the Government’s needs. The salient physical, functional, or performance characteristics that “equal” products must meet are specified in the solicitation.

(b) To be considered for award, offers of “equal” products, including “equal” products of the brand name manufacturer, must—

(1) Meet the salient physical, functional, or performance characteristic specified in this solicitation;

(2) Clearly identify the item by—

(i) Brand name, if any; and

(ii) Make or model number;

pg. 5

(3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and

(4) Clearly describe any modifications the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modifications.

(c) The Contracting Officer will evaluate “equal” products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer.

(d) Unless the offeror clearly indicates in its offer that the product being offered is an “equal” product, the offeror shall provide the brand name product referenced in the solicitation.

Offerors providing an "equal" product must submit additional documentation that highlights and describes how the offer is equal in accordance with FAR Clause 52.211-6.

52.212-1 INSTRUCTIONS TO OFFERORS-COMMERCIAL ITEMS (OCT 2018);

52.212-2 EVALUATION COMMERCIAL ITEMS (OCTOBER 2014):

52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS-COMMERCIAL ITEMS

(OCT 2018) WITH DUNS NUMBER ADDENDUM {52.204-6 (OCT 2016)};

FAR Clause 52.212-4 CONTRACT TERMS AND CONDITIONS – COMMERCIAL ITEMS

(OCT 2018);

FAR Clause 52.212-5: CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT

STATUTES OR EXECUTIVE ORDERS-COMMERCIAL ITEMS (JAN

2019). The following FAR clauses cited in paragraph (b) of the clause at FAR 52.212-5 are also applicable to this acquisition;

FAR Clause 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2018)

FAR Clause 52.209-6 Protecting the Government’s Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment (Oct 2015)

FAR Clause 52.219-6, Notice of Total Small Business Set-Aside (Nov 2011)

FAR Clause 52.219-13, Notice of Set-Aside of Orders (Nov 2011)

FAR Clause 52.219-28 Post Award Small Business Program Representation (Jul 2013)

FAR Clause 52.222-3 Convict Labor (June 2003)

FAR Clause 52.222-19 Child Labor – Cooperation with Authorities and Remedies (Jan 2018)

FAR Clause 52.222-21 Prohibition of Segregated Facilities (Apr 2015) https://acquisition.gov/sites/default/files/current/far/html/52_217_221.html#wp1136004 https://acquisition.gov/sites/default/files/current/far/html/52_217_221.html#wp1136174

pg. 6

FAR Clause 52.222-26 Equal Opportunity (Sept 2016)

FAR Clause 52.222-36 Equal Opportunity for Workers with Disabilities (July 2014)

FAR Clause 52.222-50 Combating Trafficking in Persons (Mar 2015)

FAR Clause 52.223-18 Encouraging Contractor Policies to Ban Text Messaging While Driving

(AUG 2011)

FAR Clause 52.225-1, Buy American Act--Supplies (May 2014)

FAR Clause 52.225-13 Restrictions on Certain Foreign Purchases (June 2008)

Far Clause 52.232-33 Payment by Electronic Funds Transfer–System for Award Management (SAM) (Oct 2018)

SUBMISSION INFORMATION

Quotations must be submitted via email to Contract Specialist, Kathy Elliott, at Elliottk@mail.nih.gov in MS Word or Adobe Portable Document Format (PDF), no later than 11:00 AM EST, on Friday, July 12, 2019. All responses must be received by the specified due date and time in order to be considered.

QUOTATIONS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. No collect calls will be accepted.

Please refer to solicitation no: 75N91019Q00070 on all correspondence.

Full text copies of the representations and certifications for other cited provisions and clauses may be obtained on line at the NCI website at http://ncioa.cancer.gov/oa-internet/reference.jsp

OFFERORS: Offers must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of the valid certification registrations of the offeror’s Excluded Parties List System (EPLS) and Online Representations and Certifications Applications (ORCA) through www.sam.gov.

mailto:Elliottk@mail.nih.gov http://ncioa.cancer.gov/oa-internet/reference.jsp http://www.sam.gov/

National Cancer Institute Office of Acquisitions 9609 Medical Center Drive, Room 1E126 Bethesda, MD 20892